Regeneron Pharmaceuticals (REGN)

Sector:Health Care
Super Investor Stats:
Ownership count:2
Ownership rank:348
% of all portfolios:0.021%
Hold Price * :$1051.24
History Portfolio Manager Activity Share change % change to portfolio
Q3  2024
Viking Global Investors Buy 49,870 0.19
Q4  2023
Lee Ainslie - Maverick Capital Buy 1,758 0.03
Q3  2023
Dodge & Cox Add 0.47% 7,200 0.01
Q2  2023
Dodge & Cox Add 0.36% 5,600 0.00
Q1  2023
Dodge & Cox Add 8.30% 118,200 0.11
Q3  2022
Dodge & Cox Add 6.17% 82,800 0.08
Q1  2022
Thomas Gayner - Markel Group Add 1.26% 1,000 0.01
Dodge & Cox Add 1135.15% 1,232,876 0.89
Q4  2021
Thomas Gayner - Markel Group Add 6.73% 5,000 0.04
Dodge & Cox Buy 108,609 0.07
Q3  2021
Thomas Gayner - Markel Group Add 11.23% 7,500 0.06
Polen Capital Management Buy 2,155 0.00
Lee Ainslie - Maverick Capital Buy 490 0.00
Q2  2021
Thomas Gayner - Markel Group Add 46.81% 21,300 0.15
Bill Nygren - Oakmark Select Fund Add 1450.00% 290,000 3.20
Q1  2021
Thomas Gayner - Markel Group Buy 45,500 0.30
Q4  2020
Polen Capital Management Add 3.36% 65,147 0.07
Q3  2020
Polen Capital Management Add 5.05% 93,123 0.14
Lee Ainslie - Maverick Capital Buy 588 0.01
Q2  2020
Polen Capital Management Add 7.18% 123,532 0.23
Q1  2020
Polen Capital Management Add 2.67% 44,708 0.09
Q4  2019
Polen Capital Management Add 2.08% 34,084 0.05
Q3  2019
Polen Capital Management Add 3.60% 57,097 0.07
Q2  2019
Bill Nygren - Oakmark Select Fund Add 44.19% 190,000 1.30
Q2  2018
Bill Nygren - Oakmark Select Fund Buy 600,000 3.59
Q1  2011
Dodge & Cox Buy 145,128 0.01
Q3  2010
Seth Klarman - Baupost Group Buy 1,000,000 1.71
Q1  2009
Bill & Melinda Gates Foundation Trust Buy 35,500 0.01

* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.